Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial

Table 3 Risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis

Variable		Pancreatitis, n		OR	RR (95%CI)	RRR (%)	AR (%)
		Yes	No
Group				0.4b	0.42 (0.22-0.81)	58	-138
	Naproxen	12	150
	Placebo	28	134
Sex				3b	2.67 (1.40- 5.07)	167	62.54
	Female	28	123
	Male	12	161
Age (yr)				2.4b	2.2 (1.22-3.96)	120	54.54
	< 40	15	63
	> 40	25	261
Sphincterotomy				1	1.05 (0.52-2.11)	5	4.76
	Yes	31	217
	No	9	67
Pancreatic duct injection				2.1b	1.88 (1.06-3.32)	88	46.81
	Yes	29	130
	No	16	149
Pancreatic duct cannulations				2.1	1.87 (0.93-3.74)	87	46.52
	≥ 3	12	37
	≤ 2	14	93
ERCP duration (min)				2.6b	2.30 (1.29-4.09)	130	56.52
	> 40	16	54
	< 40	24	218
Biliary duct injection				1.7	1.66 (0.76-3.63)	66	39.75
	Yes	33	236
	No	7	88

^bP < 0.01 vs Placebo. OR: Odds ratio; RR: Relative risk; RRR: Relative risk reduction; AR: Absolute risk.